Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial
The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(15)00488-x
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2016
Authors
Publisher
Elsevier BV